Skip to main content
Top
Published in: Diabetologia 4/2015

Open Access 01-04-2015 | Article

IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients

Authors: Ricardo C. Ferreira, Henry Z. Simons, Whitney S. Thompson, Antony J. Cutler, Xaquin Castro Dopico, Deborah J. Smyth, Meghavi Mashar, Helen Schuilenburg, Neil M. Walker, David B. Dunger, Chris Wallace, John A. Todd, Linda S. Wicker, Marcin L. Pekalski

Published in: Diabetologia | Issue 4/2015

Login to get access

Abstract

Aims/hypothesis

Type 1 diabetes results from the autoimmune destruction of insulin-secreting pancreatic beta cells by T cells. Despite the established role of T cells in the pathogenesis of the disease, to date, with the exception of the identification of islet-specific T effector (Teff) cells, studies have mostly failed to identify reproducible alterations in the frequency or function of T cell subsets in peripheral blood from patients with type 1 diabetes.

Methods

We assessed the production of the proinflammatory cytokines IL-21, IFN-γ and IL-17 in peripheral blood mononuclear cells from 69 patients with type 1 diabetes and 61 healthy donors. In an additional cohort of 30 patients with type 1 diabetes and 32 healthy donors, we assessed the frequency of circulating T follicular helper (Tfh) cells in whole blood. IL-21 and IL-17 production was also measured in peripheral blood mononuclear cells (PBMCs) from a subset of 46 of the 62 donors immunophenotyped for Tfh.

Results

We found a 21.9% (95% CI 5.8, 40.2; p = 3.9 × 10−3) higher frequency of IL-21+ CD45RA memory CD4+ Teffs in patients with type 1 diabetes (geometric mean 5.92% [95% CI 5.44, 6.44]) compared with healthy donors (geometric mean 4.88% [95% CI 4.33, 5.50]). Consistent with this finding, we found a 14.9% increase in circulating Tfh cells in the patients (95% CI 2.9, 26.9; p = 0.016).

Conclusions/interpretation

These results indicate that increased IL-21 production is likely to be an aetiological factor in the pathogenesis of type 1 diabetes that could be considered as a potential therapeutic target.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Atkinson MA, Maclaren NK (1994) The pathogenesis of insulin-dependent diabetes mellitus. New Engl J Med 331:1428–1436CrossRefPubMed Atkinson MA, Maclaren NK (1994) The pathogenesis of insulin-dependent diabetes mellitus. New Engl J Med 331:1428–1436CrossRefPubMed
4.
go back to reference Bradshaw EM, Raddassi K, Elyaman W et al (2009) Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 183:4432–4439CrossRefPubMedCentralPubMed Bradshaw EM, Raddassi K, Elyaman W et al (2009) Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 183:4432–4439CrossRefPubMedCentralPubMed
5.
go back to reference Honkanen J, Nieminen JK, Gao R et al (2010) IL-17 immunity in human type 1 diabetes. J Immunol 185:1959–1967CrossRefPubMed Honkanen J, Nieminen JK, Gao R et al (2010) IL-17 immunity in human type 1 diabetes. J Immunol 185:1959–1967CrossRefPubMed
6.
go back to reference Marwaha AK, Crome SQ, Panagiotopoulos C et al (2010) Cutting edge: increased Il-17–secreting T cells in children with new-onset type 1 diabetes. J Immunol 185:3814–3818CrossRefPubMed Marwaha AK, Crome SQ, Panagiotopoulos C et al (2010) Cutting edge: increased Il-17–secreting T cells in children with new-onset type 1 diabetes. J Immunol 185:3814–3818CrossRefPubMed
7.
go back to reference McClymont SA, Putnam AL, Lee MR et al (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186:3918–3926CrossRefPubMedCentralPubMed McClymont SA, Putnam AL, Lee MR et al (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186:3918–3926CrossRefPubMedCentralPubMed
8.
go back to reference Xu X, Shi Y, Cai Y et al (2013) Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLoS One 8:e79858CrossRefPubMedCentralPubMed Xu X, Shi Y, Cai Y et al (2013) Inhibition of increased circulating Tfh cell by anti-CD20 monoclonal antibody in patients with type 1 diabetes. PLoS One 8:e79858CrossRefPubMedCentralPubMed
9.
go back to reference Van Belle TL, Nierkens S, Arens R, von Herrath MG (2012) Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 36:1060–1072CrossRefPubMed Van Belle TL, Nierkens S, Arens R, von Herrath MG (2012) Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 36:1060–1072CrossRefPubMed
10.
go back to reference Barrett JC, Clayton DG, Concannon P et al (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41:703–707CrossRefPubMedCentralPubMed Barrett JC, Clayton DG, Concannon P et al (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41:703–707CrossRefPubMedCentralPubMed
11.
go back to reference Tangye SG, Ma CS, Brink R, Deenick EK (2013) The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol 13:412–426CrossRefPubMed Tangye SG, Ma CS, Brink R, Deenick EK (2013) The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol 13:412–426CrossRefPubMed
12.
go back to reference Thompson WS, Pekalski ML, Simons HZ et al (2014) Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clinical & Experimental Immunology 177:571–585CrossRef Thompson WS, Pekalski ML, Simons HZ et al (2014) Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clinical & Experimental Immunology 177:571–585CrossRef
13.
go back to reference Wang C, Kang SG, Lee J, Sun Z, Kim CH (2009) The roles of CCR6 in migration of Th17 cells and regulation of effector T cell balance in the gut. Mucosal Immunol 2:173–183CrossRefPubMedCentralPubMed Wang C, Kang SG, Lee J, Sun Z, Kim CH (2009) The roles of CCR6 in migration of Th17 cells and regulation of effector T cell balance in the gut. Mucosal Immunol 2:173–183CrossRefPubMedCentralPubMed
14.
go back to reference Kastirr I, Maglie S, Paroni M et al (2014) IL-21 is a central memory T cell–associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells. J Immunol 193:3322–3331CrossRefPubMed Kastirr I, Maglie S, Paroni M et al (2014) IL-21 is a central memory T cell–associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells. J Immunol 193:3322–3331CrossRefPubMed
15.
go back to reference Di Mitri D, Azevedo RI, Henson SM et al (2011) Reversible senescence in human CD4+CD45RA+CD27− memory T cells. J Immunol 187:2093–2100CrossRefPubMed Di Mitri D, Azevedo RI, Henson SM et al (2011) Reversible senescence in human CD4+CD45RA+CD27− memory T cells. J Immunol 187:2093–2100CrossRefPubMed
16.
go back to reference Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C (2008) A fundamental role for Interleukin-21 in the generation of T follicular helper cells. Immunity 29:127–137CrossRefPubMed Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C (2008) A fundamental role for Interleukin-21 in the generation of T follicular helper cells. Immunity 29:127–137CrossRefPubMed
17.
18.
go back to reference Nurieva RI, Podd A, Chen Y et al (2012) STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J Biol Chem 287:11234–11239CrossRefPubMedCentralPubMed Nurieva RI, Podd A, Chen Y et al (2012) STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J Biol Chem 287:11234–11239CrossRefPubMedCentralPubMed
19.
go back to reference Ballesteros-Tato A, León B, Graf Beth A et al (2012) Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36:847–856CrossRefPubMedCentralPubMed Ballesteros-Tato A, León B, Graf Beth A et al (2012) Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36:847–856CrossRefPubMedCentralPubMed
20.
go back to reference Dendrou CA, Plagnol V, Fung E et al (2009) Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 41:1011–1015CrossRefPubMedCentralPubMed Dendrou CA, Plagnol V, Fung E et al (2009) Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 41:1011–1015CrossRefPubMedCentralPubMed
21.
go back to reference Long SA, Cerosaletti K, Wan JY et al (2011) An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4+ T cells. Genes Immun 12:116–125CrossRefPubMedCentralPubMed Long SA, Cerosaletti K, Wan JY et al (2011) An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4+ T cells. Genes Immun 12:116–125CrossRefPubMedCentralPubMed
22.
go back to reference Garg G, Tyler JR, Yang JHM et al (2012) Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol 188:4644–4653 Garg G, Tyler JR, Yang JHM et al (2012) Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol 188:4644–4653
23.
go back to reference van Heel DA, Franke L, Hunt KA et al (2007) A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 39:827–829CrossRefPubMedCentralPubMed van Heel DA, Franke L, Hunt KA et al (2007) A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 39:827–829CrossRefPubMedCentralPubMed
24.
go back to reference Stahl EA, Raychaudhuri S, Remmers EF et al (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42:508–514CrossRefPubMedCentralPubMed Stahl EA, Raychaudhuri S, Remmers EF et al (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42:508–514CrossRefPubMedCentralPubMed
27.
28.
go back to reference Spolski R, Leonard WJ (2008) Interleukin-21: basic biology and implications for cancer and autoimmunity. Ann Rev Immunol 26:57–79CrossRef Spolski R, Leonard WJ (2008) Interleukin-21: basic biology and implications for cancer and autoimmunity. Ann Rev Immunol 26:57–79CrossRef
29.
go back to reference Maine CJ, Marquardt K, Cheung J, Sherman LA (2014) PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells. J Immunol 192:1415–1424CrossRefPubMedCentralPubMed Maine CJ, Marquardt K, Cheung J, Sherman LA (2014) PTPN22 controls the germinal center by influencing the numbers and activity of T follicular helper cells. J Immunol 192:1415–1424CrossRefPubMedCentralPubMed
30.
go back to reference Attridge K, Wang CJ, Wardzinski L et al (2012) IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 119:4656–4664CrossRefPubMed Attridge K, Wang CJ, Wardzinski L et al (2012) IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 119:4656–4664CrossRefPubMed
31.
go back to reference Attridge K, Kenefeck R, Wardzinski L et al (2014) IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells. J Immunol 192:2195–2201CrossRefPubMedCentralPubMed Attridge K, Kenefeck R, Wardzinski L et al (2014) IL-21 promotes CD4 T cell responses by phosphatidylinositol 3-kinase-dependent upregulation of CD86 on B cells. J Immunol 192:2195–2201CrossRefPubMedCentralPubMed
32.
go back to reference Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. New Engl J Med 361:2143–2152CrossRefPubMed Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. New Engl J Med 361:2143–2152CrossRefPubMed
33.
go back to reference Arif S, Leete P, Nguyen V et al (2014) Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 63:3835–3845CrossRefPubMed Arif S, Leete P, Nguyen V et al (2014) Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes. Diabetes 63:3835–3845CrossRefPubMed
Metadata
Title
IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients
Authors
Ricardo C. Ferreira
Henry Z. Simons
Whitney S. Thompson
Antony J. Cutler
Xaquin Castro Dopico
Deborah J. Smyth
Meghavi Mashar
Helen Schuilenburg
Neil M. Walker
David B. Dunger
Chris Wallace
John A. Todd
Linda S. Wicker
Marcin L. Pekalski
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3509-8

Other articles of this Issue 4/2015

Diabetologia 4/2015 Go to the issue

List of Referees

Referees 2014

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine